Department of Radiotherapy and Radiation Oncology, Leopoldina Hospital, Robert-Koch-Straße 10, 97422, Schweinfurt, Germany.
Strahlenther Onkol. 2022 Nov;198(11):981-993. doi: 10.1007/s00066-022-01941-2. Epub 2022 May 2.
PURPOSE: Patients with head and neck cancer (HNC) are at risk of malnutrition, especially during radiochemotherapy. We aimed to study the impact of a ketogenic diet (KD) versus an unspecified standard diet (SD) on body composition and survival in HNC patients undergoing radio(chemo)therapy. METHODS: As part of a controlled clinical trial, non-metastasized HNC patients were enrolled into either a KD (N = 11) or an SD (N = 21) group between May 2015 and May 2021. Body composition was measured weekly by bioimpedance analysis and analyzed using linear mixed effects models. Overall and progression-free survival was assessed during regular follow-up. RESULTS: A total of 7 KD and 21 SD patients completed the study and were eligible for comparative analysis. Chemotherapy was significantly associated with declines in all body composition parameters, while the KD had opposing, yet nonsignificant effects. In patients receiving chemotherapy, average weekly reductions of body mass (BM) and skeletal muscle mass (SMM) were 0.9 kg and 0.31 kg in the KD group versus 1.2 kg and 0.57 kg in the SD group, respectively. Patients in the KD group receiving no chemotherapy achieved an average increase of 0.04 kg BM and 0.12 kg SMM per week. After a median follow-up of 42 months (range 6.7-78 months) there were no significant differences in progression-free or overall survival between the groups. CONCLUSION: The KD may partially counteract the detrimental effects of radiochemotherapy on body composition in HNC patients. This should encourage further research into KDs in frail cancer patient populations and motivate their implementation as complementary therapy for selected patients.
目的:头颈部癌症(HNC)患者存在营养不良风险,尤其是在放化疗期间。本研究旨在探讨酮基饮食(KD)与未特指标准饮食(SD)对头颈部癌症放化疗患者的身体成分和生存的影响。
方法:作为一项对照临床试验的一部分,2015 年 5 月至 2021 年 5 月期间,招募非转移性 HNC 患者进入 KD 组(N=11)或 SD 组(N=21)。每周通过生物阻抗分析测量身体成分,并使用线性混合效应模型进行分析。在定期随访期间评估总生存期和无进展生存期。
结果:共有 7 名 KD 患者和 21 名 SD 患者完成了研究,可进行比较分析。化疗与所有身体成分参数的下降显著相关,而 KD 具有相反但无统计学意义的影响。在接受化疗的患者中,KD 组的 BM 和 SMM 每周平均减少 0.9kg 和 0.31kg,而 SD 组则分别减少 1.2kg 和 0.57kg。未接受化疗的 KD 组患者每周平均增加 0.04kg BM 和 0.12kg SMM。中位随访 42 个月(范围 6.7-78 个月)后,两组间无进展生存期或总生存期无显著差异。
结论:KD 可能部分抵消 HNC 患者放化疗对身体成分的不利影响。这应鼓励进一步研究在虚弱的癌症患者群体中使用 KD,并激励其作为选定患者的补充治疗。
Cochrane Database Syst Rev. 2020-6-24
Sci China Life Sci. 2025-4
Support Care Cancer. 2021-5
Crit Rev Oncol Hematol. 2020-7-12